{"id":42929,"date":"2025-10-09T14:54:24","date_gmt":"2025-10-09T06:54:24","guid":{"rendered":"https:\/\/flcube.com\/?p=42929"},"modified":"2025-10-09T14:55:11","modified_gmt":"2025-10-09T06:55:11","slug":"innocare-zenas-orelabrutinib-2-b-licensing-deal-fuels-ms-therapeutic-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42929","title":{"rendered":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>InnoCare Pharma Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>)<\/strong> announced a landmark <strong>exclusive license and subscription agreement<\/strong> with <strong>Zenas BioPharma,\u202fInc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZBIO:NASDAQ\">NASDAQ: ZBIO<\/a>)<\/strong>. The deal gives Zenas global rights to develop, manufacture and commercialise <strong>orelabrutinib<\/strong>\u2014a potent BTK inhibitor for <strong>multiple sclerosis (MS)<\/strong>\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed <strong>USD\u202f2\u202fbillion<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusivity &amp; Scope<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Orelabrutinib<\/strong>: exclusive BTK inhibitor licence for <strong>MS<\/strong> and non\u2011oncology indications <strong>outside Greater China<\/strong> (including mainland China, Hong Kong, Macau, Taiwan) and <strong>Southeast Asia<\/strong>.<\/li>\n\n\n\n<li><strong>IL\u201117AA\/AF inhibitor<\/strong>: oral, dual\u2011target inhibitor licensed globally <strong>outside Greater China &amp; Southeast Asia<\/strong>.<\/li>\n\n\n\n<li><strong>TYK2 inhibitor<\/strong>: oral, brain\u2011penetrant agent licensed <strong>globally<\/strong>.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Financial Terms<\/strong>\n<ul class=\"wp-block-list\">\n<li>Up to <strong>USD\u202f100\u202fmillion<\/strong> in upfront and milestone cash payments.<\/li>\n\n\n\n<li>Up to <strong>7,000,000<\/strong> Zenas common shares issued.<\/li>\n\n\n\n<li>Total potential transaction value >\u202fUSD\u202f2\u202fbillion, including development, regulatory, and commercial milestones.<\/li>\n\n\n\n<li>Tiered royalties (up to high\u2011teens percentages) on annual net sales of the licensed products.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For InnoCare<\/strong>: The partnership unlocks a robust revenue stream and gives it a foothold in the high\u2011growth MS market while preserving its core oncology focus.<\/li>\n\n\n\n<li><strong>For Zenas<\/strong>: Access to a proven BTK platform and two novel pre\u2011clinical compounds accelerates its pipeline diversification and positions it for a strong competitive edge in neuro\u2011inflammatory and autoimmune disease segments.<\/li>\n\n\n\n<li><strong>Market Impact<\/strong>: The $2\u202fbillion valuation underscores investor confidence in targeted therapies for MS and other immune\u2011mediated disorders, potentially spurring further collaborations across the biotech ecosystem.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100801142.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025100801142.\"><\/object><a id=\"wp-block-file--media-e081e026-f4ca-4b16-8a33-75d8133349bb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100801142.pdf\">2025100801142<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100801142.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e081e026-f4ca-4b16-8a33-75d8133349bb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42931,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,11],"tags":[65,919,327,4332,2271],"class_list":["post-42929","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-auto-immune","tag-hkg-9969","tag-innocare-pharma","tag-nasdaq-zbio","tag-zenas-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas BioPharma,\u202fInc. (NASDAQ: ZBIO). The deal gives Zenas global rights to develop, manufacture and commercialise orelabrutinib\u2014a potent BTK inhibitor for multiple sclerosis (MS)\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed USD\u202f2\u202fbillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42929\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas BioPharma,\u202fInc. (NASDAQ: ZBIO). The deal gives Zenas global rights to develop, manufacture and commercialise orelabrutinib\u2014a potent BTK inhibitor for multiple sclerosis (MS)\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed USD\u202f2\u202fbillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42929\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-09T06:54:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-09T06:55:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline\",\"datePublished\":\"2025-10-09T06:54:24+00:00\",\"dateModified\":\"2025-10-09T06:55:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0903.webp\",\"keywords\":[\"Auto-immune\",\"HKG: 9969\",\"InnoCare Pharma\",\"NASDAQ: ZBIO\",\"Zenas BioPharma\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42929#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42929\",\"name\":\"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0903.webp\",\"datePublished\":\"2025-10-09T06:54:24+00:00\",\"dateModified\":\"2025-10-09T06:55:11+00:00\",\"description\":\"InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas BioPharma,\u202fInc. (NASDAQ: ZBIO). The deal gives Zenas global rights to develop, manufacture and commercialise orelabrutinib\u2014a potent BTK inhibitor for multiple sclerosis (MS)\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed USD\u202f2\u202fbillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42929\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0903.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/0903.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42929#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas BioPharma,\u202fInc. (NASDAQ: ZBIO). The deal gives Zenas global rights to develop, manufacture and commercialise orelabrutinib\u2014a potent BTK inhibitor for multiple sclerosis (MS)\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed USD\u202f2\u202fbillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42929","og_locale":"en_US","og_type":"article","og_title":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline","og_description":"InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas BioPharma,\u202fInc. (NASDAQ: ZBIO). The deal gives Zenas global rights to develop, manufacture and commercialise orelabrutinib\u2014a potent BTK inhibitor for multiple sclerosis (MS)\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed USD\u202f2\u202fbillion.","og_url":"https:\/\/flcube.com\/?p=42929","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-09T06:54:24+00:00","article_modified_time":"2025-10-09T06:55:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42929#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42929"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline","datePublished":"2025-10-09T06:54:24+00:00","dateModified":"2025-10-09T06:55:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42929"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42929#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp","keywords":["Auto-immune","HKG: 9969","InnoCare Pharma","NASDAQ: ZBIO","Zenas BioPharma"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42929#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42929","url":"https:\/\/flcube.com\/?p=42929","name":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42929#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42929#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp","datePublished":"2025-10-09T06:54:24+00:00","dateModified":"2025-10-09T06:55:11+00:00","description":"InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas BioPharma,\u202fInc. (NASDAQ: ZBIO). The deal gives Zenas global rights to develop, manufacture and commercialise orelabrutinib\u2014a potent BTK inhibitor for multiple sclerosis (MS)\u2014alongside two other pre\u2011clinical assets, with an estimated value that could exceed USD\u202f2\u202fbillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42929#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42929"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42929#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp","width":1080,"height":608,"caption":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42929#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare, Zenas, Orelabrutinib: $2\u202fB Licensing Deal Fuels MS Therapeutic Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/0903.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42929"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42929\/revisions"}],"predecessor-version":[{"id":42934,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42929\/revisions\/42934"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42931"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}